This review summarizes the 2016 ESC guidelines for chronic heart failure, emphasizing the foundational role of neurohormonal blockade and the introduction of novel agents like ARNIs.
Answers are grounded in this paper and cite their sources.
Supports GDMT optimization in HFrEF; leaves open need for updated reviews beyond 2016 ESC guidelines.
Congestive heart failure (HF) is a morbidity that is increasing worldwide due to the aging population and improvement in (acute) care for patients with cardiovascular diseases. The prognosis for patients with HF is very poor without treatment. Furthermore, (repeated) hospitalizations for cardiac decompensation cause an increasing economic burden. Modern drugs and the consequent implementation of therapeutic recommendations have substantially improved the morbidity and mortality of HF patients. This paper provides an overview of the current pharmacological management of HF patients, based on the 2016 guidelines of the European Society of Cardiology (ESC).
No takes yet. Share an insight, caveat, or question.
Berliner et al. (2017) conducted a review in Chronic Heart Failure. Pharmacological management (ACEI, ARB, Beta-blockers, MRA, ARNI, etc.) was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: